IGHG3 and cancer: It induces strong effector functions with potent anti-cancer activities, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) (47) IgG2, however, tends to form dimers and aggregates in vivo, leading to reduced ADC drug concentrations (48) IgG3, with its notably short half-life of approximately 7 days, diminishes the therapeutic efficacy of ADCs and does not enhance Fc-mediated effector functions (49, 50).